DHR · Danaher Corp /De/
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP adjusted diluted net earnings per common share non-GAAP | $1.94 | Q2 2026 | — |
| Non-GAAP core revenue excluding respiratory testing revenue non-GAAP | 4.5% | Q2 2026 | — |
| Non-GAAP free cash flow non-GAAP | 1.3B | Q2 2026 | — |
|
|
|||
| non-GAAP core revenue non-GAAP | 0.5% | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DHR
this stock
Danaher Corp /De/
|
$140.36B | -12.4% | +8.5% | 35.4 | 1.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$213.65B | -0.1% | +0.4% | 31.1 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$46.07B | -13.6% | +10.4% | 41.1 | 2.7% |
|
A
Agilent Technologies, Inc.
|
$39.81B | +4.3% | +6.4% | 28.3 | 2.7% |
|
IQV
Iqvia Holdings Inc.
|
$39.40B | +4.7% | +41.6% | 29.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DHR | +1.6% | +4.7% | -8.9% | +2.4% | -12.4% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -3.9% | +1.4% | -20.1% | -0.7% | -25.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.